Chart Scan – Dec 29, 2022

Chart Scan – Dec 29, 2022

ABEO – Abeona Therapeutics Inc.

ACHL – Achilles Therapeutics Plc

AKBA – Akebia Therapeutics, Inc.

AKTS – Akoustis Technologies, Inc.

APTO – Aptose Biosciences, Inc.

ASTS – AST SpaceMobile, Inc.

ATHE – Alterity Therapeutics Limited

ATXG – Addentax Group Corp.

AVDX – AvidXchange Holdings Inc.

AVIR – Atea Pharmaceuticals Inc.

BGXX – Bright Green Corp.

BXRX – Baudax Bio Inc.

CABA – Cabaletta Bio Inc.

CLBT – Cellebrite DI Ltd.

CLXT – Calyxt, Inc.

CTIC – CTI BioPharma Corp.

CTMX – CytomX Therapeutics, Inc.

DAVE – Dave Inc.

DENN – Denny’s Corp.

EOSE – Eos Energy Enterprises, Inc.

FBIO – Fortress Biotech, Inc.

FWBI – First Wave BioPharma, Inc.

GEVO – Gevo Inc.

GOVX – Geovax Labs Inc.

GRIL – Muscle Maker Inc.

HYZN – Hyzon Motors Inc.

IMAB – I-Mab

IMGN – ImmunoGen, Inc.

INM – InMed Pharmaceuticals Inc.

KPTI – Karyopharm Therapeutics Inc.

KZR – Kezar Life Sciences, Inc.

LYEL – Lyell Immunopharma Inc.

MBIO – Mustang Bio, Inc.

MESA – Mesa Air Group Inc

MTTR – Matterport, Inc.

NOTV – Inotiv, Inc.

NXTC – NextCure, Inc.

OABI – OmniAb, Inc.

OPK – Opko Health Inc.

PALI – Palisade Bio, Inc.

PEGY – Pineapple Holdings, Inc.

PLYA – Playa Hotels & Resorts N.V

PSNY – Polestar Automotive Holding UK Plc

QNRX – Quoin Pharmaceuticals, Ltd.

REE – REE Automotive Ltd

RNAZ – TransCode Therapeutics Inc.

RSLS – ReShape Lifesciences, Inc.

RXRX – Recursion Pharmaceuticals Inc.

RXT – Rackspace Technology Inc.

SEAT – Vivid Seats Inc.

SGMO – Sangamo Therapeutics, Inc.

SPRO – Spero Therapeutics, Inc.

SRNE – Sorrento Therapeutics, Inc.

STRO – Sutro Biopharma Inc.

SWBI – Smith & Wesson Brands, Inc.

TCRT – Alaunos Therapeutics, Inc.

VERB – Verb Technology Co., Inc.

VRAY – ViewRay, Inc.

VYNE – VYNE Therapeutics, Inc.

Disclaimer:
We have not received any form of compensation for the generation of this blog

Any type of reproduction, copying or distribution of the material in this email is prohibited without a written consent from the site owner.

Disclaimer- By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold us, our editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.

We are not held liable or responsible for the information in press releases issued by the companies discussed in these blog. Please do your own due diligence.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments